Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors while in the central nervous system, conolidine modulates alternate molecular targets. A Science Advances analyze found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://barryh083lsg1.therainblog.com/profile